Skip to content
Screener

Jade Biosciences JBIO Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$36.98M+11.9%
Vor Biopharma logo
Vor BiopharmaVOR
-$220.33M-578%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$53.01M-34.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.94M-77.6%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
-$14M+31.8%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$21.83M-41.9%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.34B+460%
Enterprise value$1.28B+6,863%

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by Jade Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:27 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212088
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other comprehensive income (loss):
Currency translation adjustment2
Unrealized loss on investments(473)
Comprehensive loss$(40,839)$(38,169)
Net loss per share attributable to common stockholders, basic and diluted$(0.57)$(12.10)
Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted$(573.44)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted57,777,1653,155,500
Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted12,622

Item 1. Financial Statements.

FAQ

What is Jade Biosciences's comprehensive income (loss), net of tax, attributable to parent?
Jade Biosciences (JBIO) reported comprehensive income (loss), net of tax, attributable to parent of -$40.84M in Q1 2026.
How has Jade Biosciences's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Jade Biosciences's comprehensive income (loss), net of tax, attributable to parent decreased by 7.0% year-over-year, from -$38.17M to -$40.84M.
What is the long-term trend for Jade Biosciences's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Jade Biosciences's comprehensive income (loss), net of tax, attributable to parent has grown at a 53.3% compound annual growth rate (CAGR), from -$23.02M to -$127.28M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as foreign currency adjustments and unrealized gains or losses on securities. It provides a comprehensive view of the company's financial performance beyond traditional net income. Investors use this to assess the total impact of market volatility and accounting adjustments on shareholder value.

Ask your AI about Jade Biosciences's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude